Live cell therapy (Niehans)

This is a historical account. A psychotherapist has no legitimate way to practise this method. This page describes what it was and did so you can recognise it, and gives your own clinical work with clients and families who are considering it, using it, or recovering from it. Nothing here presents live cell therapy as a treatment for any disease.

1. What it was

Version(s) described: Paul Niehans's "Frischzellentherapie" (fresh or live cell therapy) as described in a 1971 on-site report from Clinique La Prairie. Also covered: the German practice of the 1950s to 2010s as summarised by the Paul-Ehrlich-Institut (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM) in 2015–2016, the 2014 Q fever outbreak reported by the CDC, and related variants (dried, frozen and extract preparations, glandular and organotherapy products).

Who, where, when. Paul Niehans (1882–1971) was a Swiss surgeon. In the early 1930s he began injecting preparations of fetal animal tissue into people for "rejuvenation". He worked from Clinique La Prairie at Clarens-Montreux on Lake Geneva. A 2008 spa-industry account dates the clinic's opening and his first fetal sheep cell injections there to 1931. [source: Quackwatch, Barrett 2003; SpaFinder 2008; Good Thinking Society] The 2016 BMG summary of the PEI and BfArM reports says the "classic" Niehans form, using living cells, reached Germany in the early 1950s. [source: BMG 2016]
Rationale as it was sold. Proponents said young cells injected into the body travel to the matching organ and strengthen or regenerate it. Preparations were therefore picked to "match" the organs thought to be failing (brain, pituitary, thyroid, adrenal, thymus, liver, kidney, heart, gonads and others). [source: Quackwatch] Claims ranged from anti-aging, vitality and "immune strengthening" to sexual function and infertility. They also included serious disease: cancer, neurological disease, Down syndrome, autism and dementia. [source: Quackwatch; BMG 2016; CDC MMWR 2015] By 2015 the CDC listed advertised uses that included erectile dysfunction, depression, and joint, neurological, heart, kidney, lung, endocrine and liver disease. [source: CDC MMWR 2015]
How it was marketed. Its reputation rested on wealthy and famous patients. The press reported Pope Pius XII and film stars among them, and some of these claims were denied or disputed at the time. Patients were anonymous and were described as fearing ageing or cancer and as needing "psychological reinforcement". In 1971 the clinic director said the clinic took "no advanced cases". [source: Skerly 1971; SpaFinder 2008] Discretion was part of the product. A Swiss critic said accidents rarely became public because patients were reluctant to admit they had sought rejuvenation. [source: Skerly 1971]
Spread and naming. The method was also known as live cell therapy, cellular therapy, cytotherapy, glandular therapy, embryonic cell therapy, siccacell therapy and organotherapy. [source: Quackwatch; Good Thinking Society] In Germany, physicians and Heilpraktiker (licensed non-medical practitioners) could legally make such preparations themselves without a manufacturing licence. More than 400 reported self-manufacture to state authorities, according to BfArM. Many patients travelled from abroad, especially from Asia. [source: BMG 2016] A German provider was reported to target clients in China, Russia and the USA. [source: DocCheck] A US group travelled to a German physician for injections regularly for about five years to support "general health and vitality". [source: CDC MMWR 2015]
Regulatory status in one line. Neither German federal regulator considers efficacy proven for any indication, and both class the products as "bedenklich" (harmful) medicines with an unfavourable risk-benefit ratio. [source: BMG 2016] The US FDA has not licensed any such product, and the CDC calls the practice unavailable in the US. [source: CDC MMWR 2015]

2. What was actually done

The sequence below describes a typical course as sources report it. Quantities, schedules and preparation details are deliberately described only in qualitative terms.

Recruitment and referral. People came through word of mouth, celebrity stories, travel groups and clinic marketing. Many travelled abroad for the treatment ("xenotourism", in the CDC's term). [source: CDC MMWR 2015; Skerly 1971]
Assessment and selection. In 1971 the La Prairie director described taking people who feared illness rather than "advanced cases". An AMA report cited at the time said Niehans selected patients likely to respond. A Swiss medical critic noted a "dearth of preliminary examinations". [source: Skerly 1971] Organ preparations were then chosen to correspond to the organs the practitioner judged weak. [source: Quackwatch]
Consent. No source shows how consent was obtained, and it is [uncertain: not verified]. The sources do show that patients were told of benefits that had no supporting evidence, and that risks were played down. German practitioners argued the residual risk was low. [source: BVerfG 2000, recording the parties' positions] In Germany there was no legal duty to report suspected adverse reactions. [source: BMG 2016]
Source animals and preparation, described qualitatively. In the classic Niehans method, a pregnant ewe was slaughtered and the fetus removed by caesarean section. Fetal and some maternal organs were separated into many organ categories, minced and suspended in salt solution, and drawn into labelled syringes. One of Niehans's rules reportedly required the clinic to be close to a butcher. [source: Skerly 1971] German regulators later found organs from slaughterhouse animals being used without any step to inactivate pathogens. They also found production was not standardised, sterility and virus-safety measures were mostly missing, and in no case reviewed was the composition of the product known. [source: BMG 2016] Sheep were the main source animals. Cattle, pigs and sharks are also reported. [source: BMG 2016; CDC MMWR 2015]
Setting and staff. Treatment took place in small private clinics or practices, often with the comfort of a hotel. A physician or Heilpraktiker made and injected the preparations. [source: Skerly 1971; BMG 2016; Aerzte Zeitung 2018]
The injections. Preparations were injected into muscle, typically the buttock. Several organ preparations were often given at one visit, and some practitioners gave many different cell types at once. [source: Skerly 1971; Quackwatch; CDC MMWR 2015] German clinics routinely premedicated patients with antihistamines and corticosteroids to suppress reactions, some before every injection. That routine shows reactions were expected. [source: BMG 2016]
Afterwards. In the classic regime patients were told to rest and eat well. They were to avoid alcohol, tobacco, sunbathing, saunas and strenuous sport, and also to avoid medications and hormones. Benefits were promised over the following months. [source: Skerly 1971] The instruction to avoid medicines is a direct route to harm when someone has a real medical condition [synthesis].
Judging "progress". Evidence for benefit rested on anecdote and patient reports, not on controlled trials. [source: BMG 2016] One German physician commented that mild immune reactions were counted as a "Therapieerfolg" (treatment success). [source: Hopf 2000] Under that logic, side effects were reframed as proof of effect.
Non-response and repetition. Clients returned for repeated courses over years. [source: CDC MMWR 2015] The 1971 report records Niehans warning against too-frequent repetition, on the theory that cells could become "lazy". [source: Skerly 1971] How refusal or non-response was handled is [uncertain: not verified].

Named variants.

Dried and frozen cells. Freeze-dried "Trockenzellen" (including a product called "Cellorgan") and frozen "Gefrierzellen". [source: BMG 2016; Skerly 1971] In 2017 a German administrative court reportedly barred a Rhineland-Palatinate clinic, "Villa Medica" in Edenkoben, from continuing frozen animal cell therapy, calling it a harmful medicine (case 5 K 903/16.NW; year inferred). [source: Aerzte Zeitung 2018]
Xenogenic organ extracts. These are extracts from animal organs that contain no intact cells: thymus extracts (calf), Polyerga (pig spleen), Ney Tumoin (bovine), and Factor AF2 (lamb spleen and liver), much of it promoted against cancer. [source: Good Thinking Society; BMG 2016]
Oral "glandular" and "cell" products. Examples are imported "Zellen-Cell Therapy" pills, which the FDA warned about in 1996, and "live cell" or bovine mesenchymal products sold in the US. [source: Quackwatch]
Earlier and parallel practices. Organ and gland implantation for "rejuvenation" in the early 20th century, including goat-gland surgery in the US. [source: Quackwatch]

3. How it caused harm

Immune reactions to foreign protein. Injecting animal proteins can trigger anaphylactic shock, which is fatal if not treated promptly. [source: Good Thinking Society] German regulators call immunological and allergic reactions inherent to these products and impossible to minimise. Case reports include fatal reactions ("bis zum Tode"). [source: BMG 2016] The CDC lists anaphylaxis, vasculitis, encephalitis, polyradiculitis, paresis and death. [source: CDC MMWR 2015] Reports from the 1980s add Guillain-Barré syndrome, leukoencephalitis, immune-complex vasculitis, encephalopathy and a blistering skin disease. A 1987 Lancet report described a woman who died in shock after very many injections. [source: Quackwatch, citing the literature]
Deaths, historically. A 1957 survey of 179 West German hospitals reportedly found 80 serious immunological reactions, 30 of them fatal. [source: Quackwatch; uncertain: secondary] Another secondary account reports about 30 deaths by 1955, and a 1975 report traced 35 German deaths to practitioners using Niehans's technique. [source: Good Thinking Society; Quackwatch citing Today's Health 1975; uncertain: secondary, figures differ]
Autoimmune and neurological injury. People with existing or latent immune disease, such as multiple sclerosis, lupus or rheumatoid arthritis, are at raised risk of autoimmune reactions. [source: BMG 2016; Hopf 2000] Delayed reactions such as leukoencephalopathy or polyneuritis are hard to attribute, which makes them easy to deny. [source: Hopf 2000] Patients can also become newly allergic to foods from the donor species. [source: BMG 2016]
Infection and zoonoses. Injection bypasses the skin and mucosal barriers. Animal organs carry viruses, bacteria and fungi, and a veterinary check cannot exclude infection in animals with no visible signs. [source: BMG 2016] Clostridial infection is listed among the reported adverse events. [source: CDC MMWR 2015] A 1975 report described two men who died of gas gangrene after fetal sheep cell injections at a Florida clinic, and the practitioner lost his licence. [source: Quackwatch, citing Today's Health 1975]
The 2014 Q fever outbreak. Six travellers, five from New York and one from Canada, aged 59 to 83, received fetal sheep cell injections from one physician in Rhineland-Palatinate in May 2014 and developed Q fever (Coxiella burnetii). Three already had atrial fibrillation, Parkinson's disease or multiple sclerosis. Symptoms included fever, fatigue, sweats, headache, cellulitis, an injection-site abscess, confusion and breathlessness. Three people still had symptoms nine to ten months later. The source sheep flock was already linked to a local human outbreak. The cases came to light only after a Canadian patient's diagnosis prompted Canadian authorities to alert Germany, and further members of the travelling group were lost to follow-up. [source: CDC MMWR 2015] The CDC warns that xenotransplantation can pass animal infections to recipients, with a theoretical risk of onward spread to contacts. [source: CDC MMWR 2015]
Prion risk. Ruminant material carries a theoretical risk of transmissible spongiform encephalopathies such as BSE or scrapie, and the production methods include no step that reduces it. [source: BMG 2016] The Federal Health Ministry also cited BSE and rabies among possible risks. [source: BVerfG 2000]
Hidden harm. In Germany there was no duty to report adverse events. Foreign patients went home, so late effects went unrecorded. Regulators state that the absence of reports does not show an absence of harm. [source: BMG 2016] Shame about seeking rejuvenation kept accidents private. [source: Skerly 1971]
Indirect harm: false hope and delayed care. Claims for cancer, neurological disease, autism and Down syndrome invite people to delay or abandon effective care, or to put a child through injections. [source: BMG 2016; Quackwatch] A 1987 Australian study of children with Down syndrome found no benefit from cell therapy. [source: Quackwatch, citing Foreman and Ward 1987] The classic instruction to avoid medicines and hormones adds a further route to harm. [source: Skerly 1971; synthesis]
Financial harm. Treatment was expensive. The 1971 report lists fees for single injections, for injection series and for clinic stays, as well as books sold by the founder. [source: Skerly 1971] Repeated trips abroad multiply the cost [synthesis].
Psychological sequelae [synthesis, no source documents these directly]: secrecy and shame, self-blame after an injury, regret about lost time with a dying relative, chronic post-infectious symptoms that may fuel health anxiety, and conflict in families split over the decision.
Most at risk. Older adults; people with autoimmune or immune disorders; people with cancer or serious neurological illness; children with Down syndrome or autism, whose parents were offered treatment; and medical tourists, whose follow-up is fragmented. [source: CDC MMWR 2015; BMG 2016; Hopf 2000; Quackwatch]

4. Recognising it today

Names and rebrandings to listen for. Fresh cells and Frischzellen; live cell or cellular therapy; cytotherapy; embryonic or fetal cell therapy; sheep cell or placenta injections; "revitalisation" injections; glandulars and organotherapy; thymus, spleen or liver extracts; dried, frozen or "siccacell" cells; xenogenic organ extracts; "cell rejuvenation" retreats. [source: Quackwatch; BMG 2016; Skerly 1971] A 2008 spa-industry article says the fetal sheep liver cell preparation used at Clinique La Prairie later became "CLP Extract", used in its "Revitalization" injections. What the clinic offers today is [uncertain: not verified]. [source: SpaFinder 2008]

Typical phrases and rationales (paraphrased from the claims sources record):

Young cells "find" and regenerate the matching tired organ.
Cells "strengthen the immune system" and act as an anti-aging or vitality cure.
One package is offered for very different problems: fatigue, sexual function, fertility, depression, dementia, cancer, autism or Down syndrome. [source: BMG 2016; CDC MMWR 2015; Quackwatch]
"Natural" or "biological", with celebrity or papal testimonials and discreet luxury settings. [source: Skerly 1971; SpaFinder 2008]
Reactions after injections are described as a sign the treatment is working. [source: Hopf 2000]

Current legal position (as sources state it).

Germany. In 1987 the Federal Health Office (Bundesgesundheitsamt) ordered the suspension ("Ruhen") of the licences of all medicines for cellular therapy that still counted as licensed finished medicines under the Medicines Act's transitional rule [source: BVerfG 2000]; the figure of 235 whole-cell preparations [source: Quackwatch; uncertain: secondary]. A 1997 federal ordinance banning fresh cells followed. In 2000 the Federal Constitutional Court (BVerfGE 102, 26; 1 BvR 420/97) voided the ordinance's ban on doctors making preparations for their own patients. The ground was federal competence, not safety, and the court expressly did not decide whether a health-based ban was justified. [source: BVerfG 2000; Hopf 2000; CDC MMWR 2015] PEI and BfArM rated the products harmful in 2015–2016, and a 2018 federal initiative followed [source: BMG 2016; Aerzte Zeitung 2018]. The 2021 Frischzellenverordnung (FrischZV, 10 May 2021, under §6 AMG as amended in 2019) now bans fresh animal cells, living or not and processed or not, as active ingredients or excipients in medicines for parenteral use in humans. Violations are punishable. Exceptions cover licensed or registered products: sera, allergens, approved advanced-therapy and authorised medicines, registered homeopathic medicines, approved clinical trials and Pharmacopoeia preparations. [source: FrischZV 2021]
United States. The FDA banned imports of cellular powders and extracts for injection in 1984 and has acted against "live cell" marketers making illegal claims [source: Quackwatch; uncertain: secondary]. In one such case a federal court in 1997 permanently enjoined a firm and a physician from importing, using or selling an injected product of neonatal rabbit and human fetal cells marketed for diabetes, holding that the FDA may regulate such cell products as biological products and new drugs [source: United States v. Loran Medical Systems 1997, as summarised by Lexplug; uncertain: secondary summary of the opinion]. No product holds a biologics licence, and any clinical study would need an investigational new drug application. [source: CDC MMWR 2015]
Canada. No xenotransplantation product is authorised for sale. [source: CDC MMWR 2015]
Elsewhere. Of 12 countries where xenotransplantation procedures were identified between 1994 and 2009, 9 had no clear national rules, which is why travel abroad continues. [source: CDC MMWR 2015]

Red flags in a client's plan, a colleague's practice or a service [synthesis, built on the features above]:

Injections of animal-derived cells, extracts or "placenta" for wellness, anti-aging or a diagnosed disease, especially when the provider makes them in-house.
Travel packages to clinics abroad, group trips, repeat "maintenance" visits.
Routine premedication against allergic reactions; advice to stop medicines or hormones; reactions reframed as healing.
No written product information, no adverse-event reporting, discouragement from telling the family doctor.
A colleague who refers to, sells, or receives payment linked to such clinics, or who shares travel-group or testimonial material with clients.

How legitimate practice differs. Licensed cell and tissue therapies work differently. Blood transfusion, bone-marrow and stem-cell transplantation for defined blood diseases, and regulated advanced-therapy medicines are given for specific indications with product licensing, quality control and adverse-event monitoring. [source: Good Thinking Society; FrischZV 2021] Genuine xenotransplantation research runs under regulator approval. In the US, FDA guidance for research recipients includes lifelong surveillance and a ban on blood or tissue donation by recipients and their intimate contacts. [source: CDC MMWR 2015] Unapproved stem-cell, exosome and other cell-based wellness products sold to consumers raise similar concerns (see the procedures guidance in this domain) [synthesis].

5. What to do instead and how to help those harmed

What to offer instead. The wishes behind live cell therapy are real: to stay vigorous, to hold off ageing, to do something about a frightening diagnosis. Each of them has a legitimate route [synthesis]:

Health in later life: routine review with the client's GP or geriatric medicine.
A specific diagnosis: the treating specialist, and licensed trials where these exist.
Cancer: the oncology team. Integrative oncology may be used alongside standard care, never instead of it (see 172), with early palliative-care referral where appropriate.
Fear of ageing, decline or death: psychological work, such as CBT for health anxiety (Domain II), acceptance- and meaning-centred approaches, and existential or dignity-focused work in serious illness.

You never perform, sell, arrange, recommend or advise on any injection, extract or product, and never advise on starting or stopping medicines. Route every medical question to the prescriber or treating physician [synthesis].

Every item below is the psychotherapist's own work. Example wording is illustrative.

5.1 Asking without judgement, and recording

Purpose: to learn about past, current or planned treatments ("cell", "glandular", "revitalisation" injections, clinics abroad), because clients often keep them secret out of shame. [source: Skerly 1971; synthesis]
Steps: Ask about complementary treatments as a routine part of every assessment and review. Use the client's own words. Ask what, where, when and who provides it, and whether their doctor knows. Record it factually in the notes, without comment.
Example language (illustrative): "Many people I see use treatments outside mainstream medicine, including clinics abroad. Is there anything like that you've tried or are thinking about? I'm asking so I understand the whole picture, not to judge."
Watch for: hesitation, minimising, or an "it's just a wellness trip" framing. It is working when the client tells you plans before travelling rather than after.

5.2 Exploring meaning, hopes and expectations

Purpose: to understand what draws the client: fear of ageing or loss of sexual function, hope in serious illness, distrust of medicine, belonging to a travel group, identity linked to wealth or exclusivity. [synthesis]
Steps: Elicit the client's explanatory model ("young cells repair my organs"), what they expect to change, and by when. Ask what it would mean if nothing changed, and what they fear most. Reflect the underlying value (vitality, control, time) apart from the method.
Example language (illustrative): "What are you hoping will be different after these treatments?" "If you imagine a year from now, what would tell you it had been worth it?"
Watch for: existential fear, grief about ageing, or a terminal prognosis that has not been absorbed. It is working when the client can name the need separately from the product.

5.3 Autonomy-respecting decision support

Purpose: to help an adult client make an informed, values-based decision without coercion. [synthesis; no published decision aid specific to this method has been verified]
Steps: Ask permission before sharing information. Offer neutral, sourced facts: German regulators rate efficacy unproven for every indication and the products harmful; documented risks include anaphylaxis, autoimmune and neurological injury, and infections such as the 2014 Q fever outbreak. [source: BMG 2016; CDC MMWR 2015] Encourage a conversation with the treating doctor before any decision. Weigh costs, risks and hoped-for gains against the client's own values. Respect the choice, and keep the door open.
Example language (illustrative): "Would it help if I shared what health regulators have published about these injections? You decide what to do with it." "Whatever you choose, I'd like you to have talked it through with your doctor first."
Watch for: feeling pressured by you, pushback, or splitting you against the doctor. It is working when the client asks their own questions of the provider and the doctor.

5.4 Coordination with the doctor (with consent)

Purpose: the CDC asks clinicians to consider Q fever and other animal-borne infections in anyone who has received live cell therapy, and to ask about xenotransplantation history. The doctor needs to know. [source: CDC MMWR 2015]
Steps: Get consent to contact the GP or specialist. Share what the client received, when and where. Prompt same-day medical review for fever, chills, sweats, an inflamed or abscessed injection site, rash, breathlessness, confusion, new weakness or numbness. Urge emergency care for signs of a severe allergic reaction. Never comment on medicines. [synthesis, symptoms from CDC MMWR 2015 and BMG 2016]
Example language (illustrative): "Your doctor needs to know about the injections to look after you properly, especially if you get a fever or the injection site gets sore. Can I help you tell them, or contact them with your permission?"
Watch for: reluctance to tell the doctor, and post-injection symptoms the client explains away as "the cells working". [source: Hopf 2000] It is working when the doctor is informed and medical follow-up is arranged.

5.5 Oncology and palliative coordination

Purpose: to stop people with cancer from delaying or abandoning effective treatment, and to support those who choose alternatives while staying connected to care. [synthesis; claims for cancer per BMG 2016 and Quackwatch]
Steps: With consent, liaise with the oncology or palliative team. Keep the client engaged with the team even if they travel. Explore a prognosis that has not been absorbed. Support conversations about goals of care, and suggest early palliative referral through the team.
Example language (illustrative): "It sounds as though part of you is looking for anything that might give you more time. Can we make sure your oncology team stays in the loop, whatever you decide?"
Watch for: missed appointments, family secrecy, rapid deterioration. It is working when the medical relationship is intact.

5.6 Grief, regret and self-blame

Purpose: to support clients or relatives after injury, death, lost time or money. [synthesis]
Steps: Validate the hope that drove the decision. Separate responsibility (unregulated providers, missing warnings) from self-blame. Work on regret with compassion-focused and grief interventions, and treat trauma symptoms after severe reactions or intensive-care stays with standard trauma-focused care.
Example language (illustrative): "You made that choice wanting more life for your mother. The risks were not made clear to you. Can we look at the guilt and the love in it together?"
Watch for: complicated grief, depression, suicidal thoughts. Assess risk using standard practice. It is working when self-blame softens and grief can move.

5.7 Family conflict

Purpose: to manage family splits over spending, risk or a relative's choice. [synthesis]
Steps: Offer a joint session with consent. Separate the values each person holds from the method. Agree what the family can support (for example "you go, but we tell your doctor"). Address blame after harm.
Example language (illustrative): "It seems you both want Dad to stay well. You disagree about how. Can we start from what you share?"
Watch for: coercion in either direction, and a client being cut off from the family. It is working when communication continues despite disagreement.

5.8 Financial harm

Purpose: treatment was expensive and repeated trips add up. [source: Skerly 1971; CDC MMWR 2015]
Steps: Ask about costs, debt and pressure to pre-pay or rebook. Look for exploitation of older or cognitively impaired clients. Signpost financial advice and consumer-protection routes.
Example language (illustrative): "How are you managing the cost? Is anyone encouraging you to book more than you planned?"
Watch for: depleted savings, pressure from a provider or group, someone else controlling the decision. It is working when the client sets limits.

5.9 Safeguarding children and adults at risk

Purpose: children with Down syndrome or autism have been offered these treatments. [source: Quackwatch; BMG 2016]
Steps: If a child is to receive or has received animal-cell injections, or is being kept from needed medical care, follow your local child-safeguarding procedure. Consult your designated safeguarding lead, involve the child's doctor, and record your actions. For adults lacking capacity or being exploited, follow adult-safeguarding procedures. Respect assent: listen to the child's own wishes and fears. [synthesis]
Example language (illustrative), to a parent: "I can see how much you want to help her. Because these injections carry serious risks for children, I need to talk with her doctor and follow our safeguarding procedures. I'd like to do that with you."
Watch for: travel plans, secrecy, missed medical appointments. It is working when the child's doctor is involved and the child is safe.

5.10 Health anxiety and persistent symptoms afterwards

Purpose: to support people with post-infectious fatigue (Q fever symptoms lasted months in some), or with worry about late reactions or prion risk. [source: CDC MMWR 2015; BMG 2016]
Steps: Make sure medical assessment is complete first. Then use established approaches for health anxiety and persistent physical symptoms, such as psychoeducation, attention and reassurance-seeking work and graded activity (see Domain II), coordinated with the doctor. [synthesis]
Example language (illustrative): "Your doctor is checking the infection side. Alongside that, we can work on how the worry is affecting your days."
Watch for: new medical symptoms. Re-refer rather than psychologising them. It is working when daily function returns.

5.11 Reporting

Purpose: harms often go unrecorded. [source: BMG 2016]
Steps: With consent, or where the law requires it, help the client or their doctor report suspected adverse reactions and illegal manufacture or marketing.
- Germany: the state (Land) medicines authorities supervise manufacture and enforce reporting under §67 AMG, unevenly between states. [source: DocCheck] PEI and BfArM are the federal authorities. [source: BMG 2016] The state medical chambers (Landesärztekammern) oversee physicians. [source: Hopf 2000]
- United States: the FDA, and state or local health departments for infections. [source: CDC MMWR 2015] Consumers, patients and health professionals can report serious reactions and product problems to the FDA's MedWatch programme online, on the consumer Form FDA 3500B or by phone. [source: FDA, Reporting Serious Problems to FDA]
- Other countries: the national medicines regulator, advertising and consumer authorities, and the provider's professional board. [synthesis]
- A colleague who refers clients to, or profits from, such treatments: raise it through your professional body. [synthesis]
Example language (illustrative): "What happened to you should be on record so others are protected. Would you like help reporting it?"
Watch for: fear of the provider, or embarrassment. It is working when a report is made, or when the client makes an informed decision not to.

Ethical duties [synthesis]: keep a stance free of conflicts of interest (no referral fees, products or travel links); give accurate information within your competence; respect autonomy while meeting safeguarding duties; document advice given and liaison made.

Handling problems [synthesis]:

Client insists and is offended: acknowledge their right to choose, keep the relationship, and ask only for the doctor to be told.
Group or travel-companion pressure: explore what belonging means to the client, and rehearse saying no.
Client already abroad or mid-course: give the warning symptoms and urge local medical care if they occur.
Rupture over your concern: name it, apologise for any sense of judgement, and return to the client's goals.

Sources

← Previous · XII-145Urine therapy Next · XII-147 →Unapproved stem-cell and exosome clinics